Helicobacter pylori vaccine development:: Facing the challenge

被引:34
作者
Aebischer, T [1 ]
Schmitt, A [1 ]
Walduck, AK [1 ]
Meyer, TF [1 ]
机构
[1] Max Planck Inst Infect Biol, Dept Mol Biol, D-10117 Berlin, Germany
关键词
Helicobacter pylori; vaccine development; mouse model; human challenge model;
D O I
10.1016/j.ijmm.2005.06.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
An effective vaccine would be a desirable way to control Helicobacter pylori-induced gastric disease. Initial studies in animal models demonstrated the feasibility of immunization and led to high hopes for a human vaccine. In the mouse model immunological approaches have to date not brought a satisfactory explanation for the mechanisms of protection against this largely luminal pathogen. Recently, transcriptome studies have identified new factors. It is now proposed that non-classical immune mediators may be the key to vaccine-induced protection. Human trials of H. pylori vaccines are going ahead but although at least some formulations are clearly immunogenic, their effectiveness remains untested. The recent development of a human challenge model has now opened up new prospects for testing candidate vaccines and this will undoubtedly have a great impact in the near future. Future priorities for H. pylori vaccine development must be a better understanding of the protective mechanisms and the identification of biomarkers which can be used as reliable predictors of efficacy in humans. Despite some important advances in recent years, important issues must be resolved before an H. pylori vaccine will become a reality. (c) 2005 Elsevier GmbH. All rights reserved.
引用
收藏
页码:343 / 353
页数:11
相关论文
共 107 条
[1]   Immunity against Helicobacter pylori:: Significance of interleukin-4 receptor α chain status and gender of infected mice [J].
Aebischer, T ;
Laforsch, S ;
Hurwitz, R ;
Brombacher, F ;
Meyer, TF .
INFECTION AND IMMUNITY, 2001, 69 (01) :556-558
[2]   Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection [J].
Akhiani, AA ;
Schön, K ;
Franzén, LE ;
Pappo, J ;
Lycke, N .
JOURNAL OF IMMUNOLOGY, 2004, 172 (08) :5024-5033
[3]   Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori [J].
Alm, RA ;
Ling, LSL ;
Moir, DT ;
King, BL ;
Brown, ED ;
Doig, PC ;
Smith, DR ;
Noonan, B ;
Guild, BC ;
deJonge, BL ;
Carmel, G ;
Tummino, PJ ;
Caruso, A ;
Uria-Nickelsen, M ;
Mills, DM ;
Ives, C ;
Gibson, R ;
Merberg, D ;
Mills, SD ;
Jiang, Q ;
Taylor, DE ;
Vovis, GF ;
Trost, TJ .
NATURE, 1999, 397 (6715) :176-180
[4]   Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers [J].
Angelakopoulos, H ;
Hohmann, EL .
INFECTION AND IMMUNITY, 2000, 68 (04) :2135-2141
[5]   Effect of sequences of the active-site dipeptides of DsbA and DsbC on in vivo folding of multidisulfide proteins in Escherichia coli [J].
Bessette, PH ;
Qiu, J ;
Bardwell, JCA ;
Swartz, JR ;
Georgiou, G .
JOURNAL OF BACTERIOLOGY, 2001, 183 (03) :980-988
[6]   EXPERIMENTAL CAMPYLOBACTER-JEJUNI INFECTION IN HUMANS [J].
BLACK, RE ;
LEVINE, MM ;
CLEMENTS, ML ;
HUGHES, TP ;
BLASER, MJ .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (03) :472-479
[7]   Clearance of Helicobacter pylori infection through immunization:: the site of T cell activation contributes to vaccine efficacy [J].
Blanchard, TG ;
Eisenberg, JC ;
Matsumoto, Y .
VACCINE, 2004, 22 (07) :888-897
[8]   Helicobacter pylori infections in IgA deficiency: Lack of role for the secretory immune system [J].
Bogstedt, AK ;
Nava, S ;
Wadstrom, T ;
Hammarstrom, L .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 105 (02) :202-204
[9]   The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms [J].
Boncristiano, M ;
Paccani, SR ;
Barone, S ;
Ulivieri, C ;
Patrussi, L ;
Ilver, D ;
Amedei, A ;
D'Elios, MM ;
Telford, JL ;
Baldari, CT .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1887-1897
[10]  
Boussioutas A, 2003, CANCER RES, V63, P2569